8
M. Hedidi et al. / Tetrahedron xxx (2016) 1e10
(CH3), 111.6 (C), 116.9 (CH), 123.6 (CH), 142.5 (CH), 155.3 (C). These
data are in accordance with those previously described.52
1d (CCDC 1450720, room temperature): C6H5I2NO, M¼360.91, or-
ꢂ
thorhombic, P b c a, a¼13.2964(7), b¼8.6329(3), c¼15.5558(7) A,
3
ꢁ3
ꢂ
V¼1785.60(14) A , Z¼8, d¼2.685 g cm
,
m
¼6.982 mmꢁ1. A final
4.2.2. 4-Iodo-3-methoxypyridine (1c). The general procedure 1 us-
ing 3-methoxypyridine (0.10 mL) gave 1c (eluent: heptane-AcOEt
20:80) in 85% yield as a pale yellow powder: mp 88e90 ꢂC; IR
refinement on F2 with 2035 unique intensities and 93 parameters
converged at
u
R(F2)¼0.0730 (R(F)¼0.0311) for 1679 observed re-
flections with I>2
s
(I).
(ATR): 720, 815, 1015, 1065, 1196, 1250, 1281, 1403, 1473, 1558 cmꢁ1
;
1H NMR (CDCl3)
d
3.98 (s, 3H), 7.72 (d, 1H, J¼5.1 Hz), 7.87 (d, 1H,
4.3.2. 3-Fluoro-2,4-diiodopyridine (2d). The general procedure 2
using 3-fluoropyridine (43 L) gave 2d (eluent: heptane-AcOEt
90:10) in 94% yield as a yellow powder: mp 102 ꢂC (lit.54 102 ꢂC);
1H NMR (CDCl3)
7.63 (dd, 1H, J¼4.8 and 4.2 Hz), 7.82 (dd, 1H, J¼5.1
and 0.9 Hz); 13C NMR (CDCl3)
J¼5.1 Hz), 8.10 (s, 1H). The 1H NMR data are in accordance with
m
those previously described.23 13C NMR (CDCl3)
132.9 (CH), 134.4 (CH), 143.0 (CH), 155.2 (C).
d 57.1 (CH3), 97.4 (C),
d
d
91.1 (d, C, J¼17 Hz), 105.4 (d, C,
4.2.3. 3-Fluoro-2-iodopyridine (2b). The general procedure 1 using
3-fluoropyridine (86 L) gave 2b (eluent: CH2Cl2) in 57% yield as
J¼32 Hz), 134.0 (d, CH, J¼1.1 Hz), 146.9 (d, CH, J¼6.2 Hz), 158.6 (d, C,
J¼254 Hz). Crystal data for 2d (CCDC 1450721, T¼150 K): C5H2FI2N,
m
a yellow oil: 1H NMR (CDCl3)
d
7.29e7.42 (m, 2H), 8.25 (dt, 1H, J¼4.5
M¼348.88, triclinic, P -1, a¼7.1039(4), b¼7.8955(5), c¼7.9442(5) A,
ꢂ
and 1.5 Hz). The 1H NMR data are in accordance with those pre-
viously described.53
a
¼109.945(2),
b
¼105.973(2),
g
¼102.495(2) , V¼378.21(4) A , Z¼2,
3
ꢂ
ꢂ
d¼3.063 g cmꢁ3
,
m
¼8.244 mmꢁ1. A final refinement on F2 with 1737
unique intensities and 83 parameters converged at
u
s(I).
R(F2)¼0.1171
4.2.4. 3-Iodo-4-methoxypyridine (3b). The general procedure 1
using 4-methoxypyridine (0.10 mL) gave 3b (eluent: heptane-
AcOEt 20:80) in 89% yield as a pale yellow powder: mp 62e64 ꢂC
(R(F)¼0.0389) for 1639 observed reflections with I>2
4.3.3. 3,5-Diiodo-2,6-dimethoxypyridine (6c). The general pro-
cedure 2, but with a contact time of 20 h with the base, using 2,6-
(lit.10h 64 ꢂC); 1H NMR (CDCl3)
d
3.95 (s, 3H), 6.78 (d, 1H, J¼5.7 Hz),
8.40 (d, 1H, J¼5.4 Hz), 8.75 (s, 1H). The 1H NMR data are in accor-
dimethoxypyridine (66 mL) gave 6c (eluent: heptane-CH2Cl2 60:40)
dance with those previously reported.10h 13C NMR (CDCl3)
(CH3), 84.6 (C), 106.5 (CH), 150.1 (CH), 156.8 (CH), 163.2 (C).
d
55.7
in 30% yield as a pale yellow powder: mp 126 ꢂC; IR (ATR): 708, 736,
908, 999, 1038, 1235, 1247, 1288, 1315, 1385, 1361, 1459, 1552,
2948 cmꢁ1
(CDCl3)
for 6c (CCDC 1450723, T¼150 K): C7H7I2NO2, M¼390.94, mono-
; d
1H NMR (CDCl3) 3.96 (s, 6H), 8.16 (s, 1H); 13C NMR
4.2.5. 2-Fluoro-3,6-diiodopyridine (5c). The general procedure 1
d 54.9 (2CH3), 66.8 (2C), 156.8 (CH), 161.3 (2C). Crystal data
using 2-fluoropyridine (86
mL) gave 5c (eluent: heptane-AcOEt
10:90) in 15% yield as a pale yellow powder: mp 88 ꢂC (lit.10d
89 ꢂC); IR (ATR): 671, 727, 823, 871, 1010, 1114, 1135, 1226, 1257,
clinic,
b
P
21/c, a¼8.2579(3), b¼8.6432(3), c¼14.7789(6) A,
3
ꢂ
ꢂ
¼104.7150(10)ꢂ, V¼1020.24(7) A , Z¼4, d¼2.545
g ,
cmꢁ3
1368, 1416, 1531, 1548, 3508 cmꢁ1; 1H NMR (CDCl3)
d
7.38 (dd, 1H,
m
¼6.128 mmꢁ1. A final refinement on F2 with 2337 unique in-
J¼7.8 Hz), 7.75 (t, 1H, J¼8.0 Hz). These 1H NMR data are in accor-
tensities and 112 parameters converged at
0.0174) for 2190 observed reflections with I>2s(I).
u
R(F2)¼0.0433 (R(F)¼
dance with those previously described.10d
4.2.6. 2,6-Difluoro-3-iodopyridine (8b). The general procedure 1
4.4. General procedure 3
using 2,6-difluoropyridine (91
10:90) in 66% yield as a white powder: mp<50 ꢂC; 1H NMR (CDCl3)
6.69 (ddd, 1H, J¼8.4, 3.0 and 0.9 Hz), 8.19 (td, 1H, J¼8.1 and
7.8 Hz); 13C NMR (CDCl3)
CH, J¼35 and 5.9 Hz), 153.6 (dd, CH, J¼7.4 Hz), 160.3 (dd, C, J¼241
and 14 Hz), 162.0 (dd, C, J¼247 and 13 Hz). These data are in ac-
cordance with those previously reported.30
mL) gave 8b (eluent: heptane-AcOEt
To
a
stirred, cooled (0 ꢂC) solution of 2,2,6,6-
d
tetramethylpiperidine (0.25 mL, 1.5 mmol) in THF (2e3 mL) were
successively added BuLi (about 1.6 M hexanes solution, 1.5 mmol)
and, 5 min later, ZnCl2$TMEDA51 (0.13 g, 0.50 mmol). The mixture
was stirred for 15 min at 0 ꢂC before introduction of the substrate
(0.5 mmol) at 0e10 ꢂC. After 2 h at room temperature, a solution of
I2 (0.38 g, 1.5 mmol) in THF (4 mL) was added. The mixture was
stirred overnight before addition of an aqueous saturated solution
of Na2S2O3 (4 mL) and extraction with AcOEt (3ꢃ20 mL). The
combined organic layers were dried over MgSO4, filtered and
concentrated under reduced pressure. Purification by chromatog-
raphy on silica gel (the eluent is given in the product description)
led to the compounds described below.
d
69.3 (dd, C, J¼40 and 5.9 Hz), 108.4 (dd,
4.3. General procedure 2
To
a
stirred, cooled (0 ꢂC) solution of 2,2,6,6-
tetramethylpiperidine (0.50 mL, 3.0 mmol) in THF (5 mL) were
successively added BuLi (about 1.6 M hexanes solution, 3.0 mmol)
and, 5 min later, ZnCl2$TMEDA51 (0.26 g, 1.0 mmol). The mixture
was stirred for 15 min at 0 ꢂC before introduction of the substrate
(0.5 mmol) at 0e10 ꢂC. After 2 h at room temperature, a solution of
I2 (0.76 g, 3.0 mmol) in THF (8 mL) was added. The mixture was
stirred overnight before addition of an aqueous saturated solution
of Na2S2O3 (8 mL) and extraction with AcOEt (3ꢃ30 mL). The
combined organic layers were dried over MgSO4, filtered and
concentrated under reduced pressure. Purification by chromatog-
raphy on silica gel (the eluent is given in the product description)
led to the compounds described below.
4.4.1. 3-Fluoro-4-iodopyridine (2c). The general procedure 3 using
3-fluoropyridine (43
mL) gave 2c (eluent: hexane-CH2Cl2 80:20) in
45% yield as a yellow powder: mp 94 ꢂC (lit.53 96 ꢂC); IR (ATR): 1415,
1475, 1550, 1570, 3060 cmꢁ1 1H NMR (CDCl3)
; d 7.75 (t, 1H,
J¼5.1 Hz), 8.10 (d, 1H, J¼5.1 Hz), 8.35 (s, 1H); 13C NMR (CDCl3)
d 92.4
(d, C, J¼23 Hz), 133.7 (s, CH), 137.1 (d, CH, J¼26 Hz), 145.6 (d, CH,
J¼5.1 Hz), 159.1 (d, C, J¼256 Hz).
4.4.2. 3,5-Diiodo-4-methoxypyridine (3c). The general procedure 3
4.3.1. 2,4-Diiodo-3-methoxypyridine (1d).10h The general procedure
using 4-methoxypyridine (51
20:80) in an estimated 7% yield. It was identified by NMR: 1H
NMR (CDCl3) 3.91 (s, 3H), 8.72 (s, 2H).
mL) gave 3c (eluent: heptane-AcOEt
2 using 3-methoxypyridine (50 mL) gave 1d (eluent: heptane-AcOEt
20:80) in 35% yield as a pale yellow powder: mp 146e148 ꢂC; IR
d
(ATR): 698, 810, 840, 919, 978, 1012, 1185, 1247, 1358, 1452, 1523,
1540, 1717, 2931, 3345 cmꢁ1; 1H NMR (CDCl3)
d
3.92 (s, 3H), 7.66 (d,
4.4.3. 2,3-Diiodo-4-methoxypyridine (3d). The general procedure 3
using 4-methoxypyridine (51 L) gave 3d (eluent: heptane-AcOEt
20:80) in an estimated 2% yield. It was identified by NMR: 1H
1H, J¼5.1 Hz), 7.74 (d, 1H, J¼5.1 Hz); 13C NMR (CDCl3)
d
61.2 (CH3),
m
100.9 (C), 115.2 (C), 134.3 (CH), 146.8 (CH), 157.1 (C). Crystal data for